SlideShare a Scribd company logo
LOSART
(Losartan Potassium)
Business Plan 2015
Prevalence of Hypertension
in Bangladesh
 According to WHO, 18 percent of
people have Hypertension.
 According to NHF, 20-25 percent of
people have Hypertension.
 According to NICVD, 20 percent of
people have Hypertension.
According to different renowned
organization reports, at least 1
people of Bangladesh have
Hypertension out of 5.
Cardiovascular market
in Bangladesh
Cardiovascular market is 988 cr. with
11% growth and 9.3% share of
market.
Antihypertensive market is 636 cr.
and 64% of cardiovascular market.
Why Losartan?
• First antihypertensive generic which
crossed 100 crore and as combination
added another 86 crore. Losartan & its
combination has been taking 29.24%
share from antihypertensive market.
• Second prescribed generic in
antihypertensive drugs in terms of
units.
Brand Health
Issues & Opportunities
1. Generic market of Losartan is always positive from 2012. In next 4 yrs,
it will be 150 cr./yr.
2. Because of negative growth of Prosan (Bxm) and higher growth of
LOSART than generic, we have opportunity to take 3rd
position in IMS
market with satisfactory market share.
Issues & Opportunities
1. Generic market of Losartan is always positive from 2012. In next 4 yrs,
it will be 150 cr./yr.
2. Because of negative growth of Prosan (Bxm) and higher growth of
LOSART than generic, we have opportunity to take 3rd
position in IMS
market with satisfactory market share.
TerapeuticgroupCAGRValgr CAGRUnitgr Value(Cr.) Valuegr MS% Unitgr Value(Cr.) Valuegr MS% Unitgr Value(Cr.) Valuegr MS% Unitgr
Total 30.04 27.28 110 12.26 9.03 98.26 13.51 -3.09 86.6 32.26 23.51
Osartil 34.62 34.28 42.62 12.42 38.64 11.94 37.9 22.36 38.58 6.31 31 29.92 35.79 15.25
Angilock 33.33 33.29 37.16 17.11 33.69 15.51 31.7 21.02 32.29 5.24 26.2 30.35 30.29 15.87
Prosan 38.2 38.95 7.73 -12.43 7.01 -22.1 8.8 16.35 8.99 -5.87 7.5 28.28 8.77 11.6
LOSART 13.5 13.8 3.6 45.5 3.3 44 2.5 -17.5 2.5 -33 3 64 3.5 54.7
Losardil 26.27 26.29 2.8 -14.64 2.54 -14.68 3.2 16.1 3.34 15.1 2.8 38.24 3.27 38.29
Losan 6.83 5.48 2.6 35.73 2.4 25.89 1.9 -46.83 2.0 -56.73 3.6 58.98 4.2 58.77
20122014 2013
Brand Health-Internal
Issues
1. Overall brand growth from 2013 to 2014 is satisfactory (42%).
2. Growth of LOSART is higher than generic & also leading brands .
3. Brand position is 4 & has gained 3.3%.IMS share.
Opportunities
1. Due to negative growth of Prosan (Bxm) and higher growth of LOSART than
generic, we have opportunity to take 3rd
position in IMS market.
2. Our continuous promotion & communication with RSM, Internal Rx, sales,
growth of LOSART is increasing day by day. We hopeful about our team to help
us to increase sales through more Rx share in future.
Issues
1. Overall brand growth from 2013 to 2014 is satisfactory (42%).
2. Growth of LOSART is higher than generic & also leading brands .
3. Brand position is 4 & has gained 3.3%.IMS share.
Opportunities
1. Due to negative growth of Prosan (Bxm) and higher growth of LOSART than
generic, we have opportunity to take 3rd
position in IMS market.
2. Our continuous promotion & communication with RSM, Internal Rx, sales,
growth of LOSART is increasing day by day. We hopeful about our team to help
us to increase sales through more Rx share in future.
Sales2013(Cr.) Target2014(Cr.) ActualSepYTD(Cr.)
LE2014
(Cr.)
%Ach Gr% %ConttoDiv PCPM
4.01 5.97 3.55 5.7 95 42 0.6 3945
Specialty Contribution
Issues & Opportunities
LOSART is a chronic care products and majority % of Rx
is prescribed by specialty doctors. Within specialty
prescriber, We need to increase Rx of Cardiologist,
Diabetologist & Neurologist.
Issues & Opportunities
LOSART is a chronic care products and majority % of Rx
is prescribed by specialty doctors. Within specialty
prescriber, We need to increase Rx of Cardiologist,
Diabetologist & Neurologist.
Specialty (Top 5
for the molecule)
Molecular
contribution %
Brand
Contributio
Our Rx. Gr. % Mol.Rx. Gr. %
Cardiologist 11.6 5.9 -18 5
Diabetologist 9.4 2.9 -33 4
Medicine 19.9 5.6 -10 5
Neuro & Psychiatry 5 3.8 -31 -14
Hospital 8.8 3.4 17 17
GP 31 5.3 -2 -2
Customer matrix
2014 2015
Primary Speciality Universe no. No. Resourced Resource plan
1 Cardiologist 2500 148 1700
2 Diabetologist 1500 44 500
3 Medicine 6078 340 3000
4 Uro & nephrologist 400 8 70
5 Neuro & Psychiatry 400 15 175
Total 539 5445
2014 2015
Secondary Speciality Universe no. No. Resourced Resource plan
1 GP 15600 827 1000
Total 827 1000
Pack health
Interpretation
1. As usual trend market is being lead by 50 mg tablet,
then 25 mg & 100 mg. Our SKU contribution is as per
market.
Interpretation
1. As usual trend market is being lead by 50 mg tablet,
then 25 mg & 100 mg. Our SKU contribution is as per
market.
Pack strength
Value
(Crore)
% gr
%
contribution
(to total
25 mg 15.7 12 14
50 mg 87.6 11.4 80
100 mg 7 25.5 6
LOSART 25 mg 0.42 33 11.6
LOSART 50 mg 3.1 46.6 85.6
LOSART 100 mg 0.1 71 2.8
Pack analysis
MAT 14
Opportunities
•Positive market growth
•No. 3 competitor lost it share
•Accepted generic by doctors
•Prevalence of hypertension is
increasing day by day
Opportunities
•Positive market growth
•No. 3 competitor lost it share
•Accepted generic by doctors
•Prevalence of hypertension is
increasing day by day
Strength
•Full range of strength
•Have a good acceptability
•Large field force
Strength
•Full range of strength
•Have a good acceptability
•Large field force
Weakness
•Less specialty focus
•Low achievement in metro area
Weakness
•Less specialty focus
•Low achievement in metro area
Threats
•No. 1& 2 competitors still remain
aggressive in this market
•Direct cash investment to specialty
doctors level
Threats
•No. 1& 2 competitors still remain
aggressive in this market
•Direct cash investment to specialty
doctors level
SWOT analysis
Positives & Improvement Areas
Positives
1.Positive growth
2.Full range of strength
3.Established molecule
4.Well accepted by doctors
5.Strong sales team
6.No major complaint
regarding quality
Improvement Areas
1.Specialty wise promotion
2.New pack size (5x10’s)
may be introduced
3.Better pack design
4.Increase specialty doctors
coverage
5.Improves metro & urban
area
Need-Gap Analysis
Vis-à-vis Key Competition
Po
Gap Vs key Competition
1.Increase Rx
2. Specialty doctors
coverage
3. Improves metro & urban
area
Gap Vs key Competition
1.Increase Rx
2. Specialty doctors
coverage
3. Improves metro & urban
area
Strategy to Bridge Gap
1.Doctors & RSM wise Rx
monitoring
2.Specialty wise investment
3. Monthly & event wise
promotion
Strategy to Bridge Gap
1.Doctors & RSM wise Rx
monitoring
2.Specialty wise investment
3. Monthly & event wise
promotion
Objective 2015 (IMS)
Valin Millions
ValGr%
(over2013)
CAGRvalgr%
(over2012)
ValMS % Valin Millions Gr% MS%
Total 1100 12.26 32.2 1220 10.9
Osartil 426 12.42 30 38.64 500 17.4 41.0
Angilock 371 17.11 30.5 33.69 420 13.2 34.4
Prosan 77 -12.43 29 7.01 54 -29.9 4.4
LOSART 36 45.5 64 3.27 60 66.7 4.9
Brand Justabove
us
874 5.7 31 79.45 920 5.3 75.4
Market projection
Therapeuticgroup
(Molecule)
MAT2014 Projected MAT2015
Objective 2015 (Rx share)
Average
totalRx
Rxshare%
TotalRxavg
monthly
Rxshare% Gr%
Total 4588 5400 18
Osartil 1500 32.7 1700 31.5 13
Angilock 1289 28.1 1450 26.9 12
LOSART 225 4.9 375 6.9 67
Prosan 229 5 170 3.1 -26
BrandJustaboveus 2790 60.8 3150 58.3 13
Projected20152014Therapeutic
group
(Molecule)
Rxshareprojection
Objective 2015 (PCPM)
Growth objective : 43%
MS objective : 4.9
PCPM objective : 6921
Rank Objective : 3rd
Growth objective : 43%
MS objective : 4.9
PCPM objective : 6921
Rank Objective : 3rd
LE(Projection)Cr. PCPM SalesobjectiveCr. Gr% PCPM
LOSART 5.7 4582 10 43 6921
2014 Projcted2015
Brand
PCPMprojection
Strategic statement
We will achieve 10 crore with 43% growth for LOSART and
4.4 crore with 24% growth for LOSART PLUS in the next
year.
Communication Strategy
USP:
1.LOSART ensures effective blood pressure control &
improves CV outcomes
2.Besides BP controls, LOSART effective in CHF &
stroke
3.LOSART provides renal protection in diabetic patients
4.LOSART improves patients compliance by once daily
dosing
Payoff:
A perfect choice for hypertensive patients with stroke,
CHF & diabetic nephropathy
Payoff:
A perfect choice for hypertensive patients with stroke,
CHF & diabetic nephropathy
Brand usage
• Key Indications (specialty wise)
Cardiologist/
Diabetologist/
Nephrologist
Cardiologist/
Diabetologist/
Nephrologist
Hypertension, Congestive Heart
Failure with diabetes, stroke, renal
impairment (CKD) and
dyslipidemia
Hypertension, Congestive Heart
Failure with diabetes, stroke, renal
impairment (CKD) and
dyslipidemia
Medicine/
Neurologist
Medicine/
Neurologist
Hypertension, Congestive Heart
Failure, stroke
Hypertension, Congestive Heart
Failure, stroke
Potential GPPotential GP HypertensionHypertension
Key campaign initiatives
Objective
Campaign (Short
description)
Tgt Doctor
Specialty
Tgt doctorno Frequency Input
One tablet for
triple protection
We will promote
LOSART prevents heart
attack, stroke &
improves CHF
Cardio, Dia,
Med, Neuro
5375 3
1Literature
2Gift
Sample
For wishing World
Hypertension Day
We will promote
LOSART more
aggressively a successful
World Hypertension Day
Cardio,
Diabeto, Med,
Neuro, Nephro
5445 3
1Literature
4Gift
Sample
Controls
hypertension with
renal protection
We will promote
LOSART kidney friendly
antihypertensive
Dia, Nephro 570 3
1Literature
1Gift
1S.pad
Sample
A simple &
economic solution
for Hypertension
We will promote
LOSART & ARBs with
cost effective way
Cardio,
Diabeto, Med,
Neuro, Nephro
5375 3
1Literature
3Gift
1S.pad
Medico – Marketing initiatives
Objective Content
Doctor
Specialty
Doctor
Nos
Nos. of
programs
Costper
Program
Sales/Yr Investment ROI
To
increase
brand
image
CMEonstroke
&CHFandits
management
Cardiologist 30 16 40000 81000000 640000 1800000
Books
Objective Content
Doctor
Specialty
Doctor
Nos
Cost per
Program
Investment
To
increase
brand
image
BOOK (Kumar &
Clark's Cases in
Clinical
Medicine 3e)
Cardiology,
Medicine
800 775 620000
To
increase
brand
image
Oxford
Handbook of
Cardiology
Cardiology 600 713 427800
LOSART Resource analysis Q-1
(Feb/Mar/Apr)
SN Name of inputs
Type
(LBL/Gift/Ne
ws
letter/FLA)
Total no. No. MPE No/MPE
Month of
Dist.
Cost/input Total Cost
1 Family Lit Lit-1 8000 800 10 Feb 12 96000
2 Gift-1 Gift-1 2400 300 8 Feb 100 240000
3 Pen Gift-2 2800 350 8 March 30 84000
4 Card-Bioshakh PPM 2000 250 8 April 10 20000
5 Bioshakh Gift 1000 200 5 April 150 150000
590000
SN Name of inputs
Type
(LBL/Gift/Ne
ws
letter/FLA)
Total no. No. MPE No/MPE
Month of
Dist.
Cost/input Total Cost
1 Family Lit Lit-1 2000 200 10 Feb 12 24000
2 Card-Bioshakh PPM 1200 200 6 April 10 12000
3 Bioshakh Gift 800 200 4 April 80 64000
100000
690000
Primary customers (Cadio + Diabeto + Medi + Nepro + Neuro)
Total
Institution budget
Total
Total Q-1
LOSART Resource analysis Q-2
(May/Jun/Jul)
SN Name of inputs
Type
(LBL/Gift/Ne
ws
letter/FLA)
Total no. No. MPE No/MPE
Month of
Dist.
Cost/input Total Cost
1 Family Lit Lit-2 8000 800 10 May 5 40000
2 Gift (WHD) Gift 1800 300 6 May 120 216000
3 Ramadan PPM 1500 250 6 June 5 7500
4 Ramadan Gift Gift 1500 250 6 June 100 150000
5 Eid Card PPM 1500 250 6 July 10 15000
6 Eid Gift Gift 1500 250 6 July 150 225000
653500
SN Name of inputs
Type
(LBL/Gift/Ne
ws
letter/FLA)
Total no. No. MPE No/MPE
Month of
Dist.
Cost/input Total Cost
1 Family Lit Lit-2 1600 200 8 May 5 8000
2 Gift (WHD) Gift 600 200 3 May 120 72000
3 Ramadan PPM 800 200 4 June 5 4000
4 Ramadan Gift Gift 800 200 4 June 100 80000
0
164000
817500Total Q-2
Primary customers (Cadio + Diabeto + Medi + Nepro + Neuro)
Total
Institution budget
Total
LOSART Resource analysis Q-3
(Aug/Sep/Oct)
SN Name of inputs
Type
(LBL/Gift/Ne
ws
letter/FLA)
Total no. No. MPE No/MPE
Month of
Dist.
Cost/input Total Cost
1 Show card PPM 4000 500 8 August 5 20000
2 Gift Gift 4000 500 8 October 50 200000
220000
SN Name of inputs
Type
(LBL/Gift/Ne
ws
letter/FLA)
Total no. No. MPE No/MPE
Month of
Dist.
Cost/input Total Cost
1 Show card PPM 800 200 4 August 5 4000
2 S. pad PPM 800 200 4 October 10 8000
12000
232000
Institution budget
Total
Primary customers (Cadio + Diabeto + Medi +Nepro +Neuro)
Total Q-3
Total
LOSART Resource analysis Q-1
(Nov/Dec/Jan)
SN Name of inputs
Type
(LBL/Gift/Ne
ws
letter/FLA)
Total no. No. MPE No/MPE
Month of
Dist.
Cost/input Total Cost
1 Lit-4 PPM 5600 700 8 November 5 28000
2 Gift (16th Dec) Gift 1000 250 4 December 100 100000
3 New year gift-1 Gift 1000 250 4 December 120 120000
4 New year gift-2 Gift 1000 250 4 January 100 100000
348000
SN Name of inputs
Type
(LBL/Gift/Ne
ws
letter/FLA)
Total no. No. MPE No/MPE
Month of
Dist.
Cost/input Total Cost
1 Lit-4 PPM 800 200 4 Feb 5 4000
2 Pen Gift 800 200 4 Feb 20 16000
20000
368000Total Q-4
Institution budget
Total
Primary customers (Cadio + Diabeto + Medi + Nepro + Neuro)
Total
Sample plan
Total Sample cost :
15,04,819 TK/year (COG)
Total Sample cost :
15,04,819 TK/year (COG)
Brand Unit(1's/2's)
Noof
Dr./MPEto
sample
Unitpervisit
Totalvisitwith
sample/month
Unit/MPE/mon
th
Total
unit/mont
h
Total
unit/year
Total
value/ye
ar
LOSART50mg 4 8 2 2 31 31040 186240 1504819
Totalsamplecost 1504819
Brand expense sales ratio
Brand Projectedval2015 TotalGC2015
LOSART 100000000 0
LOSARTPLUS 44000000 0
0
Total 144000000 0
4917387
3.41
Totalpromo2015
Totalpromo%tosale
THANK YOU

More Related Content

What's hot

Marketing Plan Final
Marketing Plan FinalMarketing Plan Final
Marketing Plan Final
Teeka
 
Rosuvastatin final marketing plan
Rosuvastatin final marketing planRosuvastatin final marketing plan
Rosuvastatin final marketing plan
Asiful alam
 
Brand plan for 2010 glycomet (us vitamin) - mitesh shah
Brand plan for 2010   glycomet (us vitamin) - mitesh shahBrand plan for 2010   glycomet (us vitamin) - mitesh shah
Brand plan for 2010 glycomet (us vitamin) - mitesh shah
Mitesh Shah
 
Brand plan on cough syrup
Brand plan on cough syrup Brand plan on cough syrup
Brand plan on cough syrup
Animesh Gupta
 
Etizola brand plan
Etizola brand planEtizola brand plan
Etizola brand plan
Best HealthSciences UK
 
Marketing Presentation For 2011 MBA Program
Marketing Presentation For 2011 MBA ProgramMarketing Presentation For 2011 MBA Program
Marketing Presentation For 2011 MBA Program
jreidglass1
 
Brand Plan for the launch of Brand-X
Brand Plan for the launch of Brand-XBrand Plan for the launch of Brand-X
Brand Plan for the launch of Brand-X
Satyajit Hui
 
Coo 10 step marketing plan
Coo 10 step marketing planCoo 10 step marketing plan
Coo 10 step marketing plan
Joseph Coo
 
Team 3
Team 3Team 3
Team 3
Mariam Reyad
 
Marketing of a pharma (Basic)
Marketing of a pharma (Basic)Marketing of a pharma (Basic)
Marketing of a pharma (Basic)
Arsalan Humayun
 
Pharmaceutical Sales in Pakistan
Pharmaceutical Sales in PakistanPharmaceutical Sales in Pakistan
Pharmaceutical Sales in Pakistan
Muhammad Ali Jehangir
 
Ten Step Marketing Plan for RiteMed Metformin HCl
Ten Step Marketing Plan for RiteMed Metformin HClTen Step Marketing Plan for RiteMed Metformin HCl
Ten Step Marketing Plan for RiteMed Metformin HCl
reachjoemar
 
Pharmaceutical Marketing Strategy
Pharmaceutical Marketing StrategyPharmaceutical Marketing Strategy
Pharmaceutical Marketing Strategy
Awais e Siraj
 
New launching strategy of pharmaceutical brand
New launching strategy of pharmaceutical brandNew launching strategy of pharmaceutical brand
New launching strategy of pharmaceutical brand
Mohammad Masum Chowdhury
 
New Launch Strategy & Product Cycle
New Launch Strategy & Product CycleNew Launch Strategy & Product Cycle
New Launch Strategy & Product Cycle
Muhammad Ali Jehangir
 
How to Make Pharmaceutical Marketing Plan
How to Make Pharmaceutical Marketing PlanHow to Make Pharmaceutical Marketing Plan
How to Make Pharmaceutical Marketing Plan
Muhammad Ali Jehangir
 
Clamoxyl ppt 5.3.18
Clamoxyl ppt 5.3.18Clamoxyl ppt 5.3.18
Clamoxyl ppt 5.3.18
Atul Prajapati
 
Moxikind CV- Brand Plan
Moxikind CV- Brand PlanMoxikind CV- Brand Plan
Moxikind CV- Brand Plan
IES MCRC, Bandra
 
Diclofenac Injection BRAND PLAN
Diclofenac Injection BRAND PLANDiclofenac Injection BRAND PLAN
Diclofenac Injection BRAND PLAN
Kamal Chandra Upreti
 
Rosuvastatin
RosuvastatinRosuvastatin
Rosuvastatin
Jahanzaib Sheikh
 

What's hot (20)

Marketing Plan Final
Marketing Plan FinalMarketing Plan Final
Marketing Plan Final
 
Rosuvastatin final marketing plan
Rosuvastatin final marketing planRosuvastatin final marketing plan
Rosuvastatin final marketing plan
 
Brand plan for 2010 glycomet (us vitamin) - mitesh shah
Brand plan for 2010   glycomet (us vitamin) - mitesh shahBrand plan for 2010   glycomet (us vitamin) - mitesh shah
Brand plan for 2010 glycomet (us vitamin) - mitesh shah
 
Brand plan on cough syrup
Brand plan on cough syrup Brand plan on cough syrup
Brand plan on cough syrup
 
Etizola brand plan
Etizola brand planEtizola brand plan
Etizola brand plan
 
Marketing Presentation For 2011 MBA Program
Marketing Presentation For 2011 MBA ProgramMarketing Presentation For 2011 MBA Program
Marketing Presentation For 2011 MBA Program
 
Brand Plan for the launch of Brand-X
Brand Plan for the launch of Brand-XBrand Plan for the launch of Brand-X
Brand Plan for the launch of Brand-X
 
Coo 10 step marketing plan
Coo 10 step marketing planCoo 10 step marketing plan
Coo 10 step marketing plan
 
Team 3
Team 3Team 3
Team 3
 
Marketing of a pharma (Basic)
Marketing of a pharma (Basic)Marketing of a pharma (Basic)
Marketing of a pharma (Basic)
 
Pharmaceutical Sales in Pakistan
Pharmaceutical Sales in PakistanPharmaceutical Sales in Pakistan
Pharmaceutical Sales in Pakistan
 
Ten Step Marketing Plan for RiteMed Metformin HCl
Ten Step Marketing Plan for RiteMed Metformin HClTen Step Marketing Plan for RiteMed Metformin HCl
Ten Step Marketing Plan for RiteMed Metformin HCl
 
Pharmaceutical Marketing Strategy
Pharmaceutical Marketing StrategyPharmaceutical Marketing Strategy
Pharmaceutical Marketing Strategy
 
New launching strategy of pharmaceutical brand
New launching strategy of pharmaceutical brandNew launching strategy of pharmaceutical brand
New launching strategy of pharmaceutical brand
 
New Launch Strategy & Product Cycle
New Launch Strategy & Product CycleNew Launch Strategy & Product Cycle
New Launch Strategy & Product Cycle
 
How to Make Pharmaceutical Marketing Plan
How to Make Pharmaceutical Marketing PlanHow to Make Pharmaceutical Marketing Plan
How to Make Pharmaceutical Marketing Plan
 
Clamoxyl ppt 5.3.18
Clamoxyl ppt 5.3.18Clamoxyl ppt 5.3.18
Clamoxyl ppt 5.3.18
 
Moxikind CV- Brand Plan
Moxikind CV- Brand PlanMoxikind CV- Brand Plan
Moxikind CV- Brand Plan
 
Diclofenac Injection BRAND PLAN
Diclofenac Injection BRAND PLANDiclofenac Injection BRAND PLAN
Diclofenac Injection BRAND PLAN
 
Rosuvastatin
RosuvastatinRosuvastatin
Rosuvastatin
 

Similar to Losart (Losartan)

business development
business developmentbusiness development
business development
Modjtaba Babazadeh
 
Bulimia Nervosa Market 2023: Epidemiology, Industry Trends, Size, Share And F...
Bulimia Nervosa Market 2023: Epidemiology, Industry Trends, Size, Share And F...Bulimia Nervosa Market 2023: Epidemiology, Industry Trends, Size, Share And F...
Bulimia Nervosa Market 2023: Epidemiology, Industry Trends, Size, Share And F...
frankmorgan27
 
Nasal Polyps Market 2023: Epidemiology, Industry Trends, Size, Share And Fore...
Nasal Polyps Market 2023: Epidemiology, Industry Trends, Size, Share And Fore...Nasal Polyps Market 2023: Epidemiology, Industry Trends, Size, Share And Fore...
Nasal Polyps Market 2023: Epidemiology, Industry Trends, Size, Share And Fore...
frankmorgan27
 
Minimal Residual Disease Market 2023: Epidemiology, Industry Trends, Size, Sh...
Minimal Residual Disease Market 2023: Epidemiology, Industry Trends, Size, Sh...Minimal Residual Disease Market 2023: Epidemiology, Industry Trends, Size, Sh...
Minimal Residual Disease Market 2023: Epidemiology, Industry Trends, Size, Sh...
frankmorgan27
 
Intravenous Solutions Market Insights - Global Industry Growth and Forecast t...
Intravenous Solutions Market Insights - Global Industry Growth and Forecast t...Intravenous Solutions Market Insights - Global Industry Growth and Forecast t...
Intravenous Solutions Market Insights - Global Industry Growth and Forecast t...
Uday M
 
Glaucoma Therapeutics Market Growth, Demand and Challenges of the Key Industr...
Glaucoma Therapeutics Market Growth, Demand and Challenges of the Key Industr...Glaucoma Therapeutics Market Growth, Demand and Challenges of the Key Industr...
Glaucoma Therapeutics Market Growth, Demand and Challenges of the Key Industr...
IMARC Group
 
Scleroderma Market 2023: Epidemiology, Industry Trends, Size, Share And Forec...
Scleroderma Market 2023: Epidemiology, Industry Trends, Size, Share And Forec...Scleroderma Market 2023: Epidemiology, Industry Trends, Size, Share And Forec...
Scleroderma Market 2023: Epidemiology, Industry Trends, Size, Share And Forec...
frankmorgan27
 
Migraine Drugs Market by Product Type, Distribution Channel, End User 2024-2032
Migraine Drugs Market by Product Type, Distribution Channel, End User 2024-2032Migraine Drugs Market by Product Type, Distribution Channel, End User 2024-2032
Migraine Drugs Market by Product Type, Distribution Channel, End User 2024-2032
IMARC Group
 
Cervical Dystonia Market 2023: Epidemiology, Industry Trends, Size, Share And...
Cervical Dystonia Market 2023: Epidemiology, Industry Trends, Size, Share And...Cervical Dystonia Market 2023: Epidemiology, Industry Trends, Size, Share And...
Cervical Dystonia Market 2023: Epidemiology, Industry Trends, Size, Share And...
frankmorgan27
 
Thalassemia Market 2023: Epidemiology, Industry Trends, Size, Share And Forec...
Thalassemia Market 2023: Epidemiology, Industry Trends, Size, Share And Forec...Thalassemia Market 2023: Epidemiology, Industry Trends, Size, Share And Forec...
Thalassemia Market 2023: Epidemiology, Industry Trends, Size, Share And Forec...
frankmorgan27
 
Multiple myeloma therapeutics in major developed markets to 2021 growth dri...
Multiple myeloma therapeutics in major developed markets to 2021   growth dri...Multiple myeloma therapeutics in major developed markets to 2021   growth dri...
Multiple myeloma therapeutics in major developed markets to 2021 growth dri...
David2591
 
Companion Diagnostics Market PPT: Growth, Outlook, Demand, Keyplayer Analysis...
Companion Diagnostics Market PPT: Growth, Outlook, Demand, Keyplayer Analysis...Companion Diagnostics Market PPT: Growth, Outlook, Demand, Keyplayer Analysis...
Companion Diagnostics Market PPT: Growth, Outlook, Demand, Keyplayer Analysis...
IMARC Group
 
Traveler’s Diarrhea Market 2023: Epidemiology, Industry Trends, Size, Share A...
Traveler’s Diarrhea Market 2023: Epidemiology, Industry Trends, Size, Share A...Traveler’s Diarrhea Market 2023: Epidemiology, Industry Trends, Size, Share A...
Traveler’s Diarrhea Market 2023: Epidemiology, Industry Trends, Size, Share A...
frankmorgan27
 
Pompe Disease Treatment Market Growth, Demand and Challenges of the Key Indus...
Pompe Disease Treatment Market Growth, Demand and Challenges of the Key Indus...Pompe Disease Treatment Market Growth, Demand and Challenges of the Key Indus...
Pompe Disease Treatment Market Growth, Demand and Challenges of the Key Indus...
IMARC Group
 
Overactive Bladder Market 2023: Epidemiology, Industry Trends, Size, Share An...
Overactive Bladder Market 2023: Epidemiology, Industry Trends, Size, Share An...Overactive Bladder Market 2023: Epidemiology, Industry Trends, Size, Share An...
Overactive Bladder Market 2023: Epidemiology, Industry Trends, Size, Share An...
frankmorgan27
 
Probiotics Market.pdf
Probiotics Market.pdfProbiotics Market.pdf
Probiotics Market.pdf
RushiDalve
 
Presentation20190103 final
Presentation20190103 finalPresentation20190103 final
Presentation20190103 final
Wayne Wei
 
2016/02 - Leerink Partners HC
2016/02 - Leerink Partners HC2016/02 - Leerink Partners HC
2016/02 - Leerink Partners HC
Sanofi
 
2014 APAC Consumer Health SMR Summary by IMS Health
2014 APAC Consumer Health SMR Summary by IMS Health2014 APAC Consumer Health SMR Summary by IMS Health
2014 APAC Consumer Health SMR Summary by IMS Health
QuintilesIMS Asia Pacific
 
Infantile Spasms Therapeutics Market by Product Type, Distribution Channel, E...
Infantile Spasms Therapeutics Market by Product Type, Distribution Channel, E...Infantile Spasms Therapeutics Market by Product Type, Distribution Channel, E...
Infantile Spasms Therapeutics Market by Product Type, Distribution Channel, E...
IMARC Group
 

Similar to Losart (Losartan) (20)

business development
business developmentbusiness development
business development
 
Bulimia Nervosa Market 2023: Epidemiology, Industry Trends, Size, Share And F...
Bulimia Nervosa Market 2023: Epidemiology, Industry Trends, Size, Share And F...Bulimia Nervosa Market 2023: Epidemiology, Industry Trends, Size, Share And F...
Bulimia Nervosa Market 2023: Epidemiology, Industry Trends, Size, Share And F...
 
Nasal Polyps Market 2023: Epidemiology, Industry Trends, Size, Share And Fore...
Nasal Polyps Market 2023: Epidemiology, Industry Trends, Size, Share And Fore...Nasal Polyps Market 2023: Epidemiology, Industry Trends, Size, Share And Fore...
Nasal Polyps Market 2023: Epidemiology, Industry Trends, Size, Share And Fore...
 
Minimal Residual Disease Market 2023: Epidemiology, Industry Trends, Size, Sh...
Minimal Residual Disease Market 2023: Epidemiology, Industry Trends, Size, Sh...Minimal Residual Disease Market 2023: Epidemiology, Industry Trends, Size, Sh...
Minimal Residual Disease Market 2023: Epidemiology, Industry Trends, Size, Sh...
 
Intravenous Solutions Market Insights - Global Industry Growth and Forecast t...
Intravenous Solutions Market Insights - Global Industry Growth and Forecast t...Intravenous Solutions Market Insights - Global Industry Growth and Forecast t...
Intravenous Solutions Market Insights - Global Industry Growth and Forecast t...
 
Glaucoma Therapeutics Market Growth, Demand and Challenges of the Key Industr...
Glaucoma Therapeutics Market Growth, Demand and Challenges of the Key Industr...Glaucoma Therapeutics Market Growth, Demand and Challenges of the Key Industr...
Glaucoma Therapeutics Market Growth, Demand and Challenges of the Key Industr...
 
Scleroderma Market 2023: Epidemiology, Industry Trends, Size, Share And Forec...
Scleroderma Market 2023: Epidemiology, Industry Trends, Size, Share And Forec...Scleroderma Market 2023: Epidemiology, Industry Trends, Size, Share And Forec...
Scleroderma Market 2023: Epidemiology, Industry Trends, Size, Share And Forec...
 
Migraine Drugs Market by Product Type, Distribution Channel, End User 2024-2032
Migraine Drugs Market by Product Type, Distribution Channel, End User 2024-2032Migraine Drugs Market by Product Type, Distribution Channel, End User 2024-2032
Migraine Drugs Market by Product Type, Distribution Channel, End User 2024-2032
 
Cervical Dystonia Market 2023: Epidemiology, Industry Trends, Size, Share And...
Cervical Dystonia Market 2023: Epidemiology, Industry Trends, Size, Share And...Cervical Dystonia Market 2023: Epidemiology, Industry Trends, Size, Share And...
Cervical Dystonia Market 2023: Epidemiology, Industry Trends, Size, Share And...
 
Thalassemia Market 2023: Epidemiology, Industry Trends, Size, Share And Forec...
Thalassemia Market 2023: Epidemiology, Industry Trends, Size, Share And Forec...Thalassemia Market 2023: Epidemiology, Industry Trends, Size, Share And Forec...
Thalassemia Market 2023: Epidemiology, Industry Trends, Size, Share And Forec...
 
Multiple myeloma therapeutics in major developed markets to 2021 growth dri...
Multiple myeloma therapeutics in major developed markets to 2021   growth dri...Multiple myeloma therapeutics in major developed markets to 2021   growth dri...
Multiple myeloma therapeutics in major developed markets to 2021 growth dri...
 
Companion Diagnostics Market PPT: Growth, Outlook, Demand, Keyplayer Analysis...
Companion Diagnostics Market PPT: Growth, Outlook, Demand, Keyplayer Analysis...Companion Diagnostics Market PPT: Growth, Outlook, Demand, Keyplayer Analysis...
Companion Diagnostics Market PPT: Growth, Outlook, Demand, Keyplayer Analysis...
 
Traveler’s Diarrhea Market 2023: Epidemiology, Industry Trends, Size, Share A...
Traveler’s Diarrhea Market 2023: Epidemiology, Industry Trends, Size, Share A...Traveler’s Diarrhea Market 2023: Epidemiology, Industry Trends, Size, Share A...
Traveler’s Diarrhea Market 2023: Epidemiology, Industry Trends, Size, Share A...
 
Pompe Disease Treatment Market Growth, Demand and Challenges of the Key Indus...
Pompe Disease Treatment Market Growth, Demand and Challenges of the Key Indus...Pompe Disease Treatment Market Growth, Demand and Challenges of the Key Indus...
Pompe Disease Treatment Market Growth, Demand and Challenges of the Key Indus...
 
Overactive Bladder Market 2023: Epidemiology, Industry Trends, Size, Share An...
Overactive Bladder Market 2023: Epidemiology, Industry Trends, Size, Share An...Overactive Bladder Market 2023: Epidemiology, Industry Trends, Size, Share An...
Overactive Bladder Market 2023: Epidemiology, Industry Trends, Size, Share An...
 
Probiotics Market.pdf
Probiotics Market.pdfProbiotics Market.pdf
Probiotics Market.pdf
 
Presentation20190103 final
Presentation20190103 finalPresentation20190103 final
Presentation20190103 final
 
2016/02 - Leerink Partners HC
2016/02 - Leerink Partners HC2016/02 - Leerink Partners HC
2016/02 - Leerink Partners HC
 
2014 APAC Consumer Health SMR Summary by IMS Health
2014 APAC Consumer Health SMR Summary by IMS Health2014 APAC Consumer Health SMR Summary by IMS Health
2014 APAC Consumer Health SMR Summary by IMS Health
 
Infantile Spasms Therapeutics Market by Product Type, Distribution Channel, E...
Infantile Spasms Therapeutics Market by Product Type, Distribution Channel, E...Infantile Spasms Therapeutics Market by Product Type, Distribution Channel, E...
Infantile Spasms Therapeutics Market by Product Type, Distribution Channel, E...
 

More from Mohammed Moshiur Rahaman

Orbapin 5 20
Orbapin 5 20Orbapin 5 20
Periset.ppt
Periset.pptPeriset.ppt
Orbas
OrbasOrbas
Azolin Nasal drops (Oxymetazoline) ppt
Azolin Nasal drops (Oxymetazoline) pptAzolin Nasal drops (Oxymetazoline) ppt
Azolin Nasal drops (Oxymetazoline) ppt
Mohammed Moshiur Rahaman
 
Periset oral solution (Ondansetron) ppt.
Periset oral solution (Ondansetron) ppt.Periset oral solution (Ondansetron) ppt.
Periset oral solution (Ondansetron) ppt.
Mohammed Moshiur Rahaman
 
Unipril (Ramipril) ppt
Unipril (Ramipril) pptUnipril (Ramipril) ppt
Unipril (Ramipril) ppt
Mohammed Moshiur Rahaman
 
Betabis (Bisoprolol).ppt
Betabis (Bisoprolol).pptBetabis (Bisoprolol).ppt
Betabis (Bisoprolol).ppt
Mohammed Moshiur Rahaman
 
Current status of ARBs in BD.ppt
Current status of ARBs in BD.pptCurrent status of ARBs in BD.ppt
Current status of ARBs in BD.ppt
Mohammed Moshiur Rahaman
 

More from Mohammed Moshiur Rahaman (8)

Orbapin 5 20
Orbapin 5 20Orbapin 5 20
Orbapin 5 20
 
Periset.ppt
Periset.pptPeriset.ppt
Periset.ppt
 
Orbas
OrbasOrbas
Orbas
 
Azolin Nasal drops (Oxymetazoline) ppt
Azolin Nasal drops (Oxymetazoline) pptAzolin Nasal drops (Oxymetazoline) ppt
Azolin Nasal drops (Oxymetazoline) ppt
 
Periset oral solution (Ondansetron) ppt.
Periset oral solution (Ondansetron) ppt.Periset oral solution (Ondansetron) ppt.
Periset oral solution (Ondansetron) ppt.
 
Unipril (Ramipril) ppt
Unipril (Ramipril) pptUnipril (Ramipril) ppt
Unipril (Ramipril) ppt
 
Betabis (Bisoprolol).ppt
Betabis (Bisoprolol).pptBetabis (Bisoprolol).ppt
Betabis (Bisoprolol).ppt
 
Current status of ARBs in BD.ppt
Current status of ARBs in BD.pptCurrent status of ARBs in BD.ppt
Current status of ARBs in BD.ppt
 

Recently uploaded

Future-Proof Like Beyoncé - Syncing Email and Social Media for Iconic Brand L...
Future-Proof Like Beyoncé - Syncing Email and Social Media for Iconic Brand L...Future-Proof Like Beyoncé - Syncing Email and Social Media for Iconic Brand L...
Future-Proof Like Beyoncé - Syncing Email and Social Media for Iconic Brand L...
DigiMarCon - Digital Marketing, Media and Advertising Conferences & Exhibitions
 
Playlist and Paint Event with Sony Music U
Playlist and Paint Event with Sony Music UPlaylist and Paint Event with Sony Music U
Playlist and Paint Event with Sony Music U
SemajahParker
 
Mastering SEO for Google in the AI Era - Dennis Yu
Mastering SEO for Google in the AI Era - Dennis YuMastering SEO for Google in the AI Era - Dennis Yu
Yes, It's Your Fault Book Launch Webinar
Yes, It's Your Fault Book Launch WebinarYes, It's Your Fault Book Launch Webinar
Yes, It's Your Fault Book Launch Webinar
Demandbase
 
How to Use AI to Write a High-Quality Article that Ranks
How to Use AI to Write a High-Quality Article that RanksHow to Use AI to Write a High-Quality Article that Ranks
How to Use AI to Write a High-Quality Article that Ranks
minatamang0021
 
Mastering Your Online Visibility - Fernando Angulo
Mastering Your Online Visibility - Fernando AnguloMastering Your Online Visibility - Fernando Angulo
Luxury Hanloom Saree Brand ,Capstone Project_Kiran Bansal.pdf
Luxury Hanloom Saree Brand ,Capstone Project_Kiran Bansal.pdfLuxury Hanloom Saree Brand ,Capstone Project_Kiran Bansal.pdf
Luxury Hanloom Saree Brand ,Capstone Project_Kiran Bansal.pdf
KiranRai75
 
Etsy Marketing Guide - Tips For Selling Digital Products
Etsy Marketing Guide - Tips For Selling Digital ProductsEtsy Marketing Guide - Tips For Selling Digital Products
Etsy Marketing Guide - Tips For Selling Digital Products
kcblog21
 
Get Off the Bandwagon - Separating Digital Marketing Myths from Truth - Scott...
Get Off the Bandwagon - Separating Digital Marketing Myths from Truth - Scott...Get Off the Bandwagon - Separating Digital Marketing Myths from Truth - Scott...
Get Off the Bandwagon - Separating Digital Marketing Myths from Truth - Scott...
DigiMarCon - Digital Marketing, Media and Advertising Conferences & Exhibitions
 
How to Use a Free Book Funnel to Drive Highly Qualified Buyers Into Your Busi...
How to Use a Free Book Funnel to Drive Highly Qualified Buyers Into Your Busi...How to Use a Free Book Funnel to Drive Highly Qualified Buyers Into Your Busi...
How to Use a Free Book Funnel to Drive Highly Qualified Buyers Into Your Busi...
DigiMarCon - Digital Marketing, Media and Advertising Conferences & Exhibitions
 
How to Kickstart Content Marketing With A Small Team - Dennis Shiao
How to Kickstart Content Marketing With A Small Team - Dennis ShiaoHow to Kickstart Content Marketing With A Small Team - Dennis Shiao
How to Kickstart Content Marketing With A Small Team - Dennis Shiao
DigiMarCon - Digital Marketing, Media and Advertising Conferences & Exhibitions
 
Pillar-Based Marketing Master Class - Ryan Brock
Pillar-Based Marketing Master Class - Ryan BrockPillar-Based Marketing Master Class - Ryan Brock
Consumer Journey Mapping & Personalization Master Class - Sabrina Killgo
Consumer Journey Mapping & Personalization Master Class - Sabrina KillgoConsumer Journey Mapping & Personalization Master Class - Sabrina Killgo
Consumer Journey Mapping & Personalization Master Class - Sabrina Killgo
DigiMarCon - Digital Marketing, Media and Advertising Conferences & Exhibitions
 
Lily Ray - Optimize the Forest, Not the Trees: Move Beyond SEO Checklist - Mo...
Lily Ray - Optimize the Forest, Not the Trees: Move Beyond SEO Checklist - Mo...Lily Ray - Optimize the Forest, Not the Trees: Move Beyond SEO Checklist - Mo...
Lily Ray - Optimize the Forest, Not the Trees: Move Beyond SEO Checklist - Mo...
Amsive
 
Marketing in the Age of AI - Shifting CX from Monologue to Dialogue - Susan W...
Marketing in the Age of AI - Shifting CX from Monologue to Dialogue - Susan W...Marketing in the Age of AI - Shifting CX from Monologue to Dialogue - Susan W...
Marketing in the Age of AI - Shifting CX from Monologue to Dialogue - Susan W...
DigiMarCon - Digital Marketing, Media and Advertising Conferences & Exhibitions
 
Digital Marketing Trends - Experts Insights on How to Gain a Competitive Edge...
Digital Marketing Trends - Experts Insights on How to Gain a Competitive Edge...Digital Marketing Trends - Experts Insights on How to Gain a Competitive Edge...
Digital Marketing Trends - Experts Insights on How to Gain a Competitive Edge...
DigiMarCon - Digital Marketing, Media and Advertising Conferences & Exhibitions
 
Efficient Website Management for Digital Marketing Pros
Efficient Website Management for Digital Marketing ProsEfficient Website Management for Digital Marketing Pros
Efficient Website Management for Digital Marketing Pros
Lauren Polinsky
 
Pillar-Based Marketing - Ryan Brock, DemandJump
Pillar-Based Marketing - Ryan Brock, DemandJumpPillar-Based Marketing - Ryan Brock, DemandJump
What’s “In” and “Out” for ABM in 2024: Plays That Help You Grow and Ones to L...
What’s “In” and “Out” for ABM in 2024: Plays That Help You Grow and Ones to L...What’s “In” and “Out” for ABM in 2024: Plays That Help You Grow and Ones to L...
What’s “In” and “Out” for ABM in 2024: Plays That Help You Grow and Ones to L...
Demandbase
 

Recently uploaded (20)

Future-Proof Like Beyoncé - Syncing Email and Social Media for Iconic Brand L...
Future-Proof Like Beyoncé - Syncing Email and Social Media for Iconic Brand L...Future-Proof Like Beyoncé - Syncing Email and Social Media for Iconic Brand L...
Future-Proof Like Beyoncé - Syncing Email and Social Media for Iconic Brand L...
 
Playlist and Paint Event with Sony Music U
Playlist and Paint Event with Sony Music UPlaylist and Paint Event with Sony Music U
Playlist and Paint Event with Sony Music U
 
Mastering SEO for Google in the AI Era - Dennis Yu
Mastering SEO for Google in the AI Era - Dennis YuMastering SEO for Google in the AI Era - Dennis Yu
Mastering SEO for Google in the AI Era - Dennis Yu
 
Yes, It's Your Fault Book Launch Webinar
Yes, It's Your Fault Book Launch WebinarYes, It's Your Fault Book Launch Webinar
Yes, It's Your Fault Book Launch Webinar
 
How to Use AI to Write a High-Quality Article that Ranks
How to Use AI to Write a High-Quality Article that RanksHow to Use AI to Write a High-Quality Article that Ranks
How to Use AI to Write a High-Quality Article that Ranks
 
Mastering Your Online Visibility - Fernando Angulo
Mastering Your Online Visibility - Fernando AnguloMastering Your Online Visibility - Fernando Angulo
Mastering Your Online Visibility - Fernando Angulo
 
Luxury Hanloom Saree Brand ,Capstone Project_Kiran Bansal.pdf
Luxury Hanloom Saree Brand ,Capstone Project_Kiran Bansal.pdfLuxury Hanloom Saree Brand ,Capstone Project_Kiran Bansal.pdf
Luxury Hanloom Saree Brand ,Capstone Project_Kiran Bansal.pdf
 
Amazing and On Point - Ramon Ray, USA TODAY
Amazing and On Point - Ramon Ray, USA TODAYAmazing and On Point - Ramon Ray, USA TODAY
Amazing and On Point - Ramon Ray, USA TODAY
 
Etsy Marketing Guide - Tips For Selling Digital Products
Etsy Marketing Guide - Tips For Selling Digital ProductsEtsy Marketing Guide - Tips For Selling Digital Products
Etsy Marketing Guide - Tips For Selling Digital Products
 
Get Off the Bandwagon - Separating Digital Marketing Myths from Truth - Scott...
Get Off the Bandwagon - Separating Digital Marketing Myths from Truth - Scott...Get Off the Bandwagon - Separating Digital Marketing Myths from Truth - Scott...
Get Off the Bandwagon - Separating Digital Marketing Myths from Truth - Scott...
 
How to Use a Free Book Funnel to Drive Highly Qualified Buyers Into Your Busi...
How to Use a Free Book Funnel to Drive Highly Qualified Buyers Into Your Busi...How to Use a Free Book Funnel to Drive Highly Qualified Buyers Into Your Busi...
How to Use a Free Book Funnel to Drive Highly Qualified Buyers Into Your Busi...
 
How to Kickstart Content Marketing With A Small Team - Dennis Shiao
How to Kickstart Content Marketing With A Small Team - Dennis ShiaoHow to Kickstart Content Marketing With A Small Team - Dennis Shiao
How to Kickstart Content Marketing With A Small Team - Dennis Shiao
 
Pillar-Based Marketing Master Class - Ryan Brock
Pillar-Based Marketing Master Class - Ryan BrockPillar-Based Marketing Master Class - Ryan Brock
Pillar-Based Marketing Master Class - Ryan Brock
 
Consumer Journey Mapping & Personalization Master Class - Sabrina Killgo
Consumer Journey Mapping & Personalization Master Class - Sabrina KillgoConsumer Journey Mapping & Personalization Master Class - Sabrina Killgo
Consumer Journey Mapping & Personalization Master Class - Sabrina Killgo
 
Lily Ray - Optimize the Forest, Not the Trees: Move Beyond SEO Checklist - Mo...
Lily Ray - Optimize the Forest, Not the Trees: Move Beyond SEO Checklist - Mo...Lily Ray - Optimize the Forest, Not the Trees: Move Beyond SEO Checklist - Mo...
Lily Ray - Optimize the Forest, Not the Trees: Move Beyond SEO Checklist - Mo...
 
Marketing in the Age of AI - Shifting CX from Monologue to Dialogue - Susan W...
Marketing in the Age of AI - Shifting CX from Monologue to Dialogue - Susan W...Marketing in the Age of AI - Shifting CX from Monologue to Dialogue - Susan W...
Marketing in the Age of AI - Shifting CX from Monologue to Dialogue - Susan W...
 
Digital Marketing Trends - Experts Insights on How to Gain a Competitive Edge...
Digital Marketing Trends - Experts Insights on How to Gain a Competitive Edge...Digital Marketing Trends - Experts Insights on How to Gain a Competitive Edge...
Digital Marketing Trends - Experts Insights on How to Gain a Competitive Edge...
 
Efficient Website Management for Digital Marketing Pros
Efficient Website Management for Digital Marketing ProsEfficient Website Management for Digital Marketing Pros
Efficient Website Management for Digital Marketing Pros
 
Pillar-Based Marketing - Ryan Brock, DemandJump
Pillar-Based Marketing - Ryan Brock, DemandJumpPillar-Based Marketing - Ryan Brock, DemandJump
Pillar-Based Marketing - Ryan Brock, DemandJump
 
What’s “In” and “Out” for ABM in 2024: Plays That Help You Grow and Ones to L...
What’s “In” and “Out” for ABM in 2024: Plays That Help You Grow and Ones to L...What’s “In” and “Out” for ABM in 2024: Plays That Help You Grow and Ones to L...
What’s “In” and “Out” for ABM in 2024: Plays That Help You Grow and Ones to L...
 

Losart (Losartan)

  • 2. Prevalence of Hypertension in Bangladesh  According to WHO, 18 percent of people have Hypertension.  According to NHF, 20-25 percent of people have Hypertension.  According to NICVD, 20 percent of people have Hypertension.
  • 3. According to different renowned organization reports, at least 1 people of Bangladesh have Hypertension out of 5.
  • 4. Cardiovascular market in Bangladesh Cardiovascular market is 988 cr. with 11% growth and 9.3% share of market. Antihypertensive market is 636 cr. and 64% of cardiovascular market.
  • 5. Why Losartan? • First antihypertensive generic which crossed 100 crore and as combination added another 86 crore. Losartan & its combination has been taking 29.24% share from antihypertensive market. • Second prescribed generic in antihypertensive drugs in terms of units.
  • 6. Brand Health Issues & Opportunities 1. Generic market of Losartan is always positive from 2012. In next 4 yrs, it will be 150 cr./yr. 2. Because of negative growth of Prosan (Bxm) and higher growth of LOSART than generic, we have opportunity to take 3rd position in IMS market with satisfactory market share. Issues & Opportunities 1. Generic market of Losartan is always positive from 2012. In next 4 yrs, it will be 150 cr./yr. 2. Because of negative growth of Prosan (Bxm) and higher growth of LOSART than generic, we have opportunity to take 3rd position in IMS market with satisfactory market share. TerapeuticgroupCAGRValgr CAGRUnitgr Value(Cr.) Valuegr MS% Unitgr Value(Cr.) Valuegr MS% Unitgr Value(Cr.) Valuegr MS% Unitgr Total 30.04 27.28 110 12.26 9.03 98.26 13.51 -3.09 86.6 32.26 23.51 Osartil 34.62 34.28 42.62 12.42 38.64 11.94 37.9 22.36 38.58 6.31 31 29.92 35.79 15.25 Angilock 33.33 33.29 37.16 17.11 33.69 15.51 31.7 21.02 32.29 5.24 26.2 30.35 30.29 15.87 Prosan 38.2 38.95 7.73 -12.43 7.01 -22.1 8.8 16.35 8.99 -5.87 7.5 28.28 8.77 11.6 LOSART 13.5 13.8 3.6 45.5 3.3 44 2.5 -17.5 2.5 -33 3 64 3.5 54.7 Losardil 26.27 26.29 2.8 -14.64 2.54 -14.68 3.2 16.1 3.34 15.1 2.8 38.24 3.27 38.29 Losan 6.83 5.48 2.6 35.73 2.4 25.89 1.9 -46.83 2.0 -56.73 3.6 58.98 4.2 58.77 20122014 2013
  • 7. Brand Health-Internal Issues 1. Overall brand growth from 2013 to 2014 is satisfactory (42%). 2. Growth of LOSART is higher than generic & also leading brands . 3. Brand position is 4 & has gained 3.3%.IMS share. Opportunities 1. Due to negative growth of Prosan (Bxm) and higher growth of LOSART than generic, we have opportunity to take 3rd position in IMS market. 2. Our continuous promotion & communication with RSM, Internal Rx, sales, growth of LOSART is increasing day by day. We hopeful about our team to help us to increase sales through more Rx share in future. Issues 1. Overall brand growth from 2013 to 2014 is satisfactory (42%). 2. Growth of LOSART is higher than generic & also leading brands . 3. Brand position is 4 & has gained 3.3%.IMS share. Opportunities 1. Due to negative growth of Prosan (Bxm) and higher growth of LOSART than generic, we have opportunity to take 3rd position in IMS market. 2. Our continuous promotion & communication with RSM, Internal Rx, sales, growth of LOSART is increasing day by day. We hopeful about our team to help us to increase sales through more Rx share in future. Sales2013(Cr.) Target2014(Cr.) ActualSepYTD(Cr.) LE2014 (Cr.) %Ach Gr% %ConttoDiv PCPM 4.01 5.97 3.55 5.7 95 42 0.6 3945
  • 8. Specialty Contribution Issues & Opportunities LOSART is a chronic care products and majority % of Rx is prescribed by specialty doctors. Within specialty prescriber, We need to increase Rx of Cardiologist, Diabetologist & Neurologist. Issues & Opportunities LOSART is a chronic care products and majority % of Rx is prescribed by specialty doctors. Within specialty prescriber, We need to increase Rx of Cardiologist, Diabetologist & Neurologist. Specialty (Top 5 for the molecule) Molecular contribution % Brand Contributio Our Rx. Gr. % Mol.Rx. Gr. % Cardiologist 11.6 5.9 -18 5 Diabetologist 9.4 2.9 -33 4 Medicine 19.9 5.6 -10 5 Neuro & Psychiatry 5 3.8 -31 -14 Hospital 8.8 3.4 17 17 GP 31 5.3 -2 -2
  • 9. Customer matrix 2014 2015 Primary Speciality Universe no. No. Resourced Resource plan 1 Cardiologist 2500 148 1700 2 Diabetologist 1500 44 500 3 Medicine 6078 340 3000 4 Uro & nephrologist 400 8 70 5 Neuro & Psychiatry 400 15 175 Total 539 5445 2014 2015 Secondary Speciality Universe no. No. Resourced Resource plan 1 GP 15600 827 1000 Total 827 1000
  • 10. Pack health Interpretation 1. As usual trend market is being lead by 50 mg tablet, then 25 mg & 100 mg. Our SKU contribution is as per market. Interpretation 1. As usual trend market is being lead by 50 mg tablet, then 25 mg & 100 mg. Our SKU contribution is as per market. Pack strength Value (Crore) % gr % contribution (to total 25 mg 15.7 12 14 50 mg 87.6 11.4 80 100 mg 7 25.5 6 LOSART 25 mg 0.42 33 11.6 LOSART 50 mg 3.1 46.6 85.6 LOSART 100 mg 0.1 71 2.8 Pack analysis MAT 14
  • 11. Opportunities •Positive market growth •No. 3 competitor lost it share •Accepted generic by doctors •Prevalence of hypertension is increasing day by day Opportunities •Positive market growth •No. 3 competitor lost it share •Accepted generic by doctors •Prevalence of hypertension is increasing day by day Strength •Full range of strength •Have a good acceptability •Large field force Strength •Full range of strength •Have a good acceptability •Large field force Weakness •Less specialty focus •Low achievement in metro area Weakness •Less specialty focus •Low achievement in metro area Threats •No. 1& 2 competitors still remain aggressive in this market •Direct cash investment to specialty doctors level Threats •No. 1& 2 competitors still remain aggressive in this market •Direct cash investment to specialty doctors level SWOT analysis
  • 12. Positives & Improvement Areas Positives 1.Positive growth 2.Full range of strength 3.Established molecule 4.Well accepted by doctors 5.Strong sales team 6.No major complaint regarding quality Improvement Areas 1.Specialty wise promotion 2.New pack size (5x10’s) may be introduced 3.Better pack design 4.Increase specialty doctors coverage 5.Improves metro & urban area
  • 13. Need-Gap Analysis Vis-à-vis Key Competition Po Gap Vs key Competition 1.Increase Rx 2. Specialty doctors coverage 3. Improves metro & urban area Gap Vs key Competition 1.Increase Rx 2. Specialty doctors coverage 3. Improves metro & urban area Strategy to Bridge Gap 1.Doctors & RSM wise Rx monitoring 2.Specialty wise investment 3. Monthly & event wise promotion Strategy to Bridge Gap 1.Doctors & RSM wise Rx monitoring 2.Specialty wise investment 3. Monthly & event wise promotion
  • 14. Objective 2015 (IMS) Valin Millions ValGr% (over2013) CAGRvalgr% (over2012) ValMS % Valin Millions Gr% MS% Total 1100 12.26 32.2 1220 10.9 Osartil 426 12.42 30 38.64 500 17.4 41.0 Angilock 371 17.11 30.5 33.69 420 13.2 34.4 Prosan 77 -12.43 29 7.01 54 -29.9 4.4 LOSART 36 45.5 64 3.27 60 66.7 4.9 Brand Justabove us 874 5.7 31 79.45 920 5.3 75.4 Market projection Therapeuticgroup (Molecule) MAT2014 Projected MAT2015
  • 15. Objective 2015 (Rx share) Average totalRx Rxshare% TotalRxavg monthly Rxshare% Gr% Total 4588 5400 18 Osartil 1500 32.7 1700 31.5 13 Angilock 1289 28.1 1450 26.9 12 LOSART 225 4.9 375 6.9 67 Prosan 229 5 170 3.1 -26 BrandJustaboveus 2790 60.8 3150 58.3 13 Projected20152014Therapeutic group (Molecule) Rxshareprojection
  • 16. Objective 2015 (PCPM) Growth objective : 43% MS objective : 4.9 PCPM objective : 6921 Rank Objective : 3rd Growth objective : 43% MS objective : 4.9 PCPM objective : 6921 Rank Objective : 3rd LE(Projection)Cr. PCPM SalesobjectiveCr. Gr% PCPM LOSART 5.7 4582 10 43 6921 2014 Projcted2015 Brand PCPMprojection
  • 17. Strategic statement We will achieve 10 crore with 43% growth for LOSART and 4.4 crore with 24% growth for LOSART PLUS in the next year.
  • 18. Communication Strategy USP: 1.LOSART ensures effective blood pressure control & improves CV outcomes 2.Besides BP controls, LOSART effective in CHF & stroke 3.LOSART provides renal protection in diabetic patients 4.LOSART improves patients compliance by once daily dosing Payoff: A perfect choice for hypertensive patients with stroke, CHF & diabetic nephropathy Payoff: A perfect choice for hypertensive patients with stroke, CHF & diabetic nephropathy
  • 19. Brand usage • Key Indications (specialty wise) Cardiologist/ Diabetologist/ Nephrologist Cardiologist/ Diabetologist/ Nephrologist Hypertension, Congestive Heart Failure with diabetes, stroke, renal impairment (CKD) and dyslipidemia Hypertension, Congestive Heart Failure with diabetes, stroke, renal impairment (CKD) and dyslipidemia Medicine/ Neurologist Medicine/ Neurologist Hypertension, Congestive Heart Failure, stroke Hypertension, Congestive Heart Failure, stroke Potential GPPotential GP HypertensionHypertension
  • 20. Key campaign initiatives Objective Campaign (Short description) Tgt Doctor Specialty Tgt doctorno Frequency Input One tablet for triple protection We will promote LOSART prevents heart attack, stroke & improves CHF Cardio, Dia, Med, Neuro 5375 3 1Literature 2Gift Sample For wishing World Hypertension Day We will promote LOSART more aggressively a successful World Hypertension Day Cardio, Diabeto, Med, Neuro, Nephro 5445 3 1Literature 4Gift Sample Controls hypertension with renal protection We will promote LOSART kidney friendly antihypertensive Dia, Nephro 570 3 1Literature 1Gift 1S.pad Sample A simple & economic solution for Hypertension We will promote LOSART & ARBs with cost effective way Cardio, Diabeto, Med, Neuro, Nephro 5375 3 1Literature 3Gift 1S.pad
  • 21. Medico – Marketing initiatives Objective Content Doctor Specialty Doctor Nos Nos. of programs Costper Program Sales/Yr Investment ROI To increase brand image CMEonstroke &CHFandits management Cardiologist 30 16 40000 81000000 640000 1800000
  • 22. Books Objective Content Doctor Specialty Doctor Nos Cost per Program Investment To increase brand image BOOK (Kumar & Clark's Cases in Clinical Medicine 3e) Cardiology, Medicine 800 775 620000 To increase brand image Oxford Handbook of Cardiology Cardiology 600 713 427800
  • 23. LOSART Resource analysis Q-1 (Feb/Mar/Apr) SN Name of inputs Type (LBL/Gift/Ne ws letter/FLA) Total no. No. MPE No/MPE Month of Dist. Cost/input Total Cost 1 Family Lit Lit-1 8000 800 10 Feb 12 96000 2 Gift-1 Gift-1 2400 300 8 Feb 100 240000 3 Pen Gift-2 2800 350 8 March 30 84000 4 Card-Bioshakh PPM 2000 250 8 April 10 20000 5 Bioshakh Gift 1000 200 5 April 150 150000 590000 SN Name of inputs Type (LBL/Gift/Ne ws letter/FLA) Total no. No. MPE No/MPE Month of Dist. Cost/input Total Cost 1 Family Lit Lit-1 2000 200 10 Feb 12 24000 2 Card-Bioshakh PPM 1200 200 6 April 10 12000 3 Bioshakh Gift 800 200 4 April 80 64000 100000 690000 Primary customers (Cadio + Diabeto + Medi + Nepro + Neuro) Total Institution budget Total Total Q-1
  • 24. LOSART Resource analysis Q-2 (May/Jun/Jul) SN Name of inputs Type (LBL/Gift/Ne ws letter/FLA) Total no. No. MPE No/MPE Month of Dist. Cost/input Total Cost 1 Family Lit Lit-2 8000 800 10 May 5 40000 2 Gift (WHD) Gift 1800 300 6 May 120 216000 3 Ramadan PPM 1500 250 6 June 5 7500 4 Ramadan Gift Gift 1500 250 6 June 100 150000 5 Eid Card PPM 1500 250 6 July 10 15000 6 Eid Gift Gift 1500 250 6 July 150 225000 653500 SN Name of inputs Type (LBL/Gift/Ne ws letter/FLA) Total no. No. MPE No/MPE Month of Dist. Cost/input Total Cost 1 Family Lit Lit-2 1600 200 8 May 5 8000 2 Gift (WHD) Gift 600 200 3 May 120 72000 3 Ramadan PPM 800 200 4 June 5 4000 4 Ramadan Gift Gift 800 200 4 June 100 80000 0 164000 817500Total Q-2 Primary customers (Cadio + Diabeto + Medi + Nepro + Neuro) Total Institution budget Total
  • 25. LOSART Resource analysis Q-3 (Aug/Sep/Oct) SN Name of inputs Type (LBL/Gift/Ne ws letter/FLA) Total no. No. MPE No/MPE Month of Dist. Cost/input Total Cost 1 Show card PPM 4000 500 8 August 5 20000 2 Gift Gift 4000 500 8 October 50 200000 220000 SN Name of inputs Type (LBL/Gift/Ne ws letter/FLA) Total no. No. MPE No/MPE Month of Dist. Cost/input Total Cost 1 Show card PPM 800 200 4 August 5 4000 2 S. pad PPM 800 200 4 October 10 8000 12000 232000 Institution budget Total Primary customers (Cadio + Diabeto + Medi +Nepro +Neuro) Total Q-3 Total
  • 26. LOSART Resource analysis Q-1 (Nov/Dec/Jan) SN Name of inputs Type (LBL/Gift/Ne ws letter/FLA) Total no. No. MPE No/MPE Month of Dist. Cost/input Total Cost 1 Lit-4 PPM 5600 700 8 November 5 28000 2 Gift (16th Dec) Gift 1000 250 4 December 100 100000 3 New year gift-1 Gift 1000 250 4 December 120 120000 4 New year gift-2 Gift 1000 250 4 January 100 100000 348000 SN Name of inputs Type (LBL/Gift/Ne ws letter/FLA) Total no. No. MPE No/MPE Month of Dist. Cost/input Total Cost 1 Lit-4 PPM 800 200 4 Feb 5 4000 2 Pen Gift 800 200 4 Feb 20 16000 20000 368000Total Q-4 Institution budget Total Primary customers (Cadio + Diabeto + Medi + Nepro + Neuro) Total
  • 27. Sample plan Total Sample cost : 15,04,819 TK/year (COG) Total Sample cost : 15,04,819 TK/year (COG) Brand Unit(1's/2's) Noof Dr./MPEto sample Unitpervisit Totalvisitwith sample/month Unit/MPE/mon th Total unit/mont h Total unit/year Total value/ye ar LOSART50mg 4 8 2 2 31 31040 186240 1504819 Totalsamplecost 1504819
  • 28. Brand expense sales ratio Brand Projectedval2015 TotalGC2015 LOSART 100000000 0 LOSARTPLUS 44000000 0 0 Total 144000000 0 4917387 3.41 Totalpromo2015 Totalpromo%tosale

Editor's Notes

  1. eneric